News – Page 976 – Endpoints News

Dear Bernie: Catalyst CEO McEnany defends his $375,000 price tag on an old drug once offered for free

7 years ago

Allogene blueprints a new manufacturing complex for next-gen CAR-T; Inovio spins out neoantigen upstart with $10.5M A ...

7 years ago

Ramaswamy's rare-disease offshoot Enzyvant poaches Alexion exec Rachelle Jacques to replace Alvin Shih at the helm

7 years ago

Off-the-shelf CAR-T from stem cells? An early look at UCLA tech — licensed by Gilead

7 years ago

Merck's Roger Perlmutter pays $300M to scoop up a battered Immune Design for its I/O work

7 years ago

MPM adds $408M for its next big wave of biotech startups — and oncology still dominates the menu

7 years ago

Serono spinoff Calypso Biotech becomes resident at J&J's European incubator, raises $22M+ in Series A

7 years ago

J&J steps up alongside AbbVie to partner with fast-growing Morphic on its small molecule approach to integrins

7 years ago

FDA cites an ‘ongoing review’ for Pfizer's blockbuster Xeljanz, with implications for the class

7 years ago

Kaleido sets terms for $100M IPO; Mallinckrodt touts positive PhIII GVHD data, cuts trial short

7 years ago

Peloton raises a monster $150M in latest round, as lead drug heads for pivotal trial

7 years ago

Applying CRISPR to Duchenne, Duke researchers spotlight 1-year mouse data in Sarepta-sponsored study

7 years ago

IP trouble defers launch of Novo's long-acting hemophilia therapy

7 years ago

Deaths spur partial hold for Xencor’s CD3 bispecific for leukemia, partnered with Novartis in $2.5B deal

7 years ago

Stem cell therapies for space missions? Pluristem joins forces with NASA to combat space-related ailments

7 years ago

Backed by OrbiMed and J&J to build precision bacteria-killing tool, BiomX adds a slate of investors in $32M Series B

7 years ago

Pfizer drops 10 mg dose of best-selling Xeljanz as study spotlights cardio safety issue, higher rate of deaths

7 years ago

Merck’s PhIII liver cancer study for Keytruda fails on two key endpoints, just three months after the FDA gave it ...

7 years ago

Strike 3: Vical axes its only remaining clinical program, completing a trifecta of disasters

7 years ago

Stock activists fire back at Allergan’s defensive moves, push for a company sale

7 years ago

FDA cautions over young donor blood transfusions to treat aging, memory loss

7 years ago

AbbVie scores speedy review for RA drug upadacitinib; Merck KGaA wins CRISPR patent

7 years ago

Israel's Immune Pharma waves the white flag after failing to secure deals for inflammation drug

7 years ago

Ex-Celgene CEO Bob Hugin makes a leap back into biotech, joining an embattled Allergan's board

7 years ago

First page Previous page 973 974 975976977 978 979 Next page Last page